Monthly Archives

December 2021

Blackhawk Growth’s Digital Mind Technology Set to Pioneer Novel Treatment in Pain Management in Cancer Patients; Preparations for Phase 1 Clinical Trials Underway

  To help reduce opioid reliance, misuse and abuse  Improve mood and reduce risk of depression and related health disorders  Help cancer patients live better with illness    Vancouver, British Columbia – TheNewswire – December 20, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its wholly-owned subsidiary, Digital Mind Technology Pty…

Read More

Blackhawk Growth Announces Plan to Spin-Out Psychedelic Subsidiaries and Proposes 1:1 Distribution Ratio

  Vancouver, British Columbia – TheNewswire – December 15, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) ( “Blackhawk”), is pleased to announce that it intends to undertake a spin-out transaction whereby the shares of its wholly owned subsidiaries MindBio Therapeutics Pty. Ltd. and Digital Mind Technology Pty Ltd. will form an independent company to focus solely on the psychedelics…

Read More

Blackhawk Growth Fully Funds Phase II Clinical Trials in Psychedelics and Begins Development of Digital Mental Health Treatments

  Vancouver, British Columbia – TheNewswire – December 13, 2021 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (“Blackhawk”), is pleased to provide an update on its clinical trials for both of its wholly-owned subsidiaries MindBio Therapeutics PTY Ltd. (“MindBio”) and Digital Mind Technology PTY Ltd. (“Digital Mind”).   MindBio Clinical Trial Update   MindBio is accelerating its clinical trial program…

Read More

Blackhawk Growth to Complete Strategic Investment of Digital Mind Technology; Fully Funds Phase 1 Clinical Trial for Digital Mind and Phase 2 Clinical Trial for MindBio Therapeutics

   Highlights: Complementary acquisition of digital wellness company with AUD$2.5M cash on hand  Digital Mind Technology has a fully funded Phase 1 Clinical Trial ongoing  Adds several new high profile and leading institutional psychedelic funds as Blackhawk shareholders  MindBio Therapeutics fully funded Phase 2 Clinical Trials  Blackhawk holding leading assets in legal psychedelic and mental health therapies     Vancouver, British…

Read More

Blackhawk Growth Completes Investment in California-Based Licensed Distribution Center – TERP Wholesale, LLC, Company Generated CAD$3,902,888 Revenue in 2020

Vancouver, British Columbia – TheNewswire – December 1, 2021 – Blackhawk Growth Corp. (the “Company”) (CSE:BLR) (Frankfurt:0JJ) (CNSX:BLR.CN) is pleased to announce that it has signed a definitive purchase agreement for the acquisition of all the outstanding membership interests in TERP Wholesale, LLC (“TERP”). The acquisition was previously announced on April 15, 2021 in connection with the signing of a…

Read More